CJC-1295 (without DAC) 5 mg + Ipamorelin 5 mg

CJC-1295 (without DAC) and Ipamorelin are synthetic peptides studied for their roles in the growth hormone (GH) axis.

CJC-1295 without DAC is a tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29). The absence of the Drug Affinity Complex (DAC) results in a shorter plasma half-life compared to the DAC-conjugated version, allowing for more precise temporal control in research models. It binds to GHRH receptors on pituitary somatotrophs, stimulating the synthesis and release of endogenous growth hormone.

Ipamorelin is a pentapeptide growth hormone secretagogue that selectively activates the ghrelin receptor (GHS-R1a). Unlike earlier secretagogues, research indicates it produces a more targeted GH pulse with minimal impact on cortisol or prolactin levels in studied models.

When examined together in laboratory settings, the combination is of interest for its potential synergistic effects on pulsatile GH release: CJC-1295 (no DAC) provides sustained receptor stimulation while Ipamorelin contributes rapid, selective pulses. Researchers have explored this stack in contexts related to GH secretion patterns, IGF-1 signaling pathways, body composition markers, recovery processes, and metabolic parameters in controlled experimental systems.

This product is supplied as a 10 mg total lyophilized peptide blend (5 mg CJC-1295 without DAC + 5 mg Ipamorelin) with documented purity >98%, endotoxin testing, and heavy metal analysis. It is intended strictly for in-vitro and laboratory research purposes. Not for human or veterinary use, not a drug, and not intended to diagnose, treat, cure, or prevent any condition.